exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088992 RNA Name: hsa-miR-516b-5p RNA Type: miRNA Chromosome: chr19 Starnd: + Coordinate: Start Site(bp): 53736860 End Site(bp): 53736881 External Links: hsa-miR-516b-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand BCL2L11 chr2 111119378 111168445 + CHKB-CPT1B chr22 50568869 50582965 - CPT1B chr22 50568861 50578465 - DNAJC9 chr10 73183362 73247255 - FAM13B chr5 137937960 138051961 - FNBP4 chr11 47716494 47767443 - FOSL2 chr2 28392448 28417317 + FSD1 chr19 4304598 4323843 + GOLGA1 chr9 124878275 124948492 - HIF1AN chr10 100529072 100559998 + MAK16 chr8 33485182 33501262 + NEMP1 chr12 57055643 57088063 - NID1 chr1 235975830 236065109 - PIGS chr17 28553383 28571794 - QSER1 chr11 32892820 32993316 + RABGAP1 chr9 122940833 123104866 + S100A16 chr1 153606886 153613145 - SGPP1 chr14 63684216 63728065 - STAT3 chr17 42313324 42388568 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000698 chr16 47531309 47549512 + hsa_circ_0001727 chr7 99621041 99621930 + hsa_circ_0001495 chr5 68470703 68471364 + hsa_circ_0000825 chr18 8718421 8720494 + hsa_circ_0001387 chr4 1902352 1936989 + hsa_circ_0000038 chr1 28800065 28802803 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC016876.2 chr17 7581964 7584086 - AC079781.5 chr7 97851688 97972985 - AL157392.3 chr10 13631143 13668445 + COL4A2-AS2 chr13 110456396 110463287 - LINC00324 chr17 8220642 8224043 - LINC01184 chr5 127939152 128083172 - MIR194-2HG chr11 64889560 64893449 - NEAT1 chr11 65422774 65445540 + PCBP1-AS1 chr2 69962263 70103220 - TBC1D3P1-DHX40P1 chr17 59962363 60018975 - TUG1 chr22 30969245 30979395 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.